TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05049278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: * Continuous drug: norepinephrine 4mg \* 1@ + D5W 200 mL (20 μg/mL)~* Range: 0.03 \~ 0.09 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: * Continuous drug: phenylephrine 10mg \* 5@ + D5W 200 mL (250 μg/mL)~* Range: 0.42 \~ 1.26 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)
Study: NCT05427903

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Ice packs application for 5 minutes after IANB injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Ice packs application for 5 minutes after IANB injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine
Description: Buccal infiltration after IANB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine
Description: Buccal infiltration after IANB
Study: NCT05891912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technological devices intervention (use of tablet and big screen with games oriented to training physical and cognitive function)
Description: The treatment will be performed in 30 min sessions, twice a week during 12 weeks. the weekly sessions will include the following games:~* 1 session per week: 15min small TABLET and 15min LIGHTS game.~* 1 session per week: 15min TABLE TABLET and 15min game of VINTAGE.
Study: NCT04990492

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Paper GAD 7
Description: The paper based GAD 7 that is commonly accepted at clinics

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Paper GAD 7
Description: The paper based GAD 7 that is commonly accepted at clinics

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Voice Administered GAD 7
Description: This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Voice Administered GAD 7
Description: This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.
Study: NCT06085651

Intervention type: PROCEDURE
Intervention: Selective thoracolumbar fusion (STLF) surgery
Description: Selective thoracolumbar fusion (STLF) surgery, is an established corrective surgical technique for spinal deformities with excellent outcomes over time

Intervention type: PROCEDURE
Intervention: Selective thoracolumbar fusion (STLF) surgery
Description: Selective thoracolumbar fusion (STLF) surgery, is an established corrective surgical technique for spinal deformities with excellent outcomes over time
Study: NCT04370457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of the MyPal ePRO system
Description: Patients will be asked to complete self-report questionnaires at baseline, and every month for the first six months and at 12-month follow-up
Study: NCT06247644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device wear on skin
Description: Participant will wear the device over a period of 28 hours to assess adhesive performance and potential skin effects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device wear on skin
Description: Participant will wear the device over a period of 28 hours to assess adhesive performance and potential skin effects.
Study: NCT05128734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered orally twice daily in treatment arm 2.
Study: NCT05048537

Intervention type: RADIATION
Group type: OTHER
Intervention: 18F-FACBC PET/CT
Description: 10mCi 18F-FACBC IV injection, then whole body PET/CT after 4 mins
Study: NCT04757350

Intervention type: OTHER
Intervention: Observational research, not applicable
Description: Observational research, not applicable
Study: NCT05082129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransiCap
Description: The TransiCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransiCap
Description: The TransiCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan.
Study: NCT04098354

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: home BP telemonitoring system .
Description: Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A\&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: home BP telemonitoring system .
Description: Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A\&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
Study: NCT06268769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Pill
Description: Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus capsule
Description: Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Study: NCT05686382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Wound Infusion
Description: continuous local anesthetic infiltration of the wound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: ultrasound guided injection of local anesthetic in the fascial plane between the internal oblique and transversus abdominis muscles
Study: NCT04008602

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quick icing
Description: Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Cold
Description: Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the decreased nerve conduction velocity.
Study: NCT04792957

Intervention type: DIAGNOSTIC_TEST
Intervention: immunohistochemical methods
Description: The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.

Intervention type: DIAGNOSTIC_TEST
Intervention: immunohistochemical methods
Description: The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.

Intervention type: DIAGNOSTIC_TEST
Intervention: immunohistochemical methods
Description: The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.

Intervention type: DIAGNOSTIC_TEST
Intervention: immunohistochemical methods
Description: The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.
Study: NCT05631977

Intervention type: OTHER
Intervention: Point of care ultrasound cardiac examination
Description: The study intervention consists of a POCUS cardiac examination by site approved personal using an FDA cleared US scanner. Usual care of study participants will not be impacted.
Study: NCT06060093

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Water, 5% collagen(w/w), octoacetate (1 mM)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water, 5% collagen(w/w), octoacetate (1 mM)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: A total of 75g ketone ester supplementation will be administered in 3 bouts of 25g in order to establish intermittent exogenous ketosis: twice immediately after training, and one 30 minutes before sleep. The ketone ester used is (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
Study: NCT04620226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement
Description: Rapid Point-of-Care testing will provide participants with a HCV antibody and RNA result within 2 hours. If the participant is HCV RNA+, they will receive an inpatient consultation from a liver specialist prior to discharge. We hypothesize that this model will minimize losses in the continuum-of-care and improve linkages to care.
Study: NCT05419063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss strategies
Description: Participants will receive recommendations on how to decrease caloric intake, monitor their weight and track the related behaviors and progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-based and email feedback
Description: Participants will receive weekly text-based feedback based on dietary strategy tracking and weight tracking. Participants will receive tailored email support and synchronous problem solving sessions as needed.
Study: NCT04488497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis
Description: This intervention will help people with RA get tested for hyperlipidemia so that they can later discuss with their physician how to better treat their increased risk for cardiovascular disease.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Participants in this group will not receive peer coaches calls. They will receive additional educational materials about CVD risk and the regular care provided by their doctors.
Study: NCT04673565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Each participant in the treatment group will attend a 1-hour MI group session with 9 other participants hosted by a practicing MI therapies via Zoom at one month after the initial visit. This session will utilize MI to elicit motivation in each participant. Participants will also receive standard care delivered at in-person audiology clinic visits.
Study: NCT04523766

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness of Breath
Description: The Mindful Breathing intervention will be adapted from a validated, brief mindfulness training model. Participants will be instructed to focus on the sensations of the breath (i.e., at the tip of the nose and in the nostrils, abdomen and back) and, if a pain arises in the body, acknowledge it without judgement and return attention to the breath.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Interoceptive Mapping
Description: The MIM intervention will be adapted from the core MORE meditation practice. Participants will be instructed to (1) zoom in to deconstruct pain into its constituent affectively-valenced physical sensations and precisely map each sensation's spatial location, (2) zoom out to broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that are absent of sensation and pleasant sensations), and (3) savor any pleasant sensations or experiences occurring during the mindfulness practice.
Study: NCT05861154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) of Wavelength 660 nm will be used and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave, Irradiation time 60 Seconds; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied at the site of needle penetration.~It should be noted that before each application, the output of the laser device will be checked using the aiming beam on flat surface; both the patient and the operator will wear safety goggles during the irradiation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzocaine Gel
Description: a 20% Benzocaine topical anaesthetic gel will be applied. To increase the absorption of the topical anaesthetic gel, soft tissues will be dried with (2 x 2 cm) gauze. Topical anaesthetic gel will be applied at the site of needle penetration and left in contact with the soft tissues for one minute in order to to maximize its effect.
Study: NCT05678322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent
Description: Under development for the diagnosis of prostate cancer by Blue Earth Diagnostics. rhPSMA-7.3 (18F) will be administered intravenously as a single-dose injection. The molecular structure of the drug substance comprises a prostate-specific membrane antigen (PSMA) binding motif, a peptide spacer, an 18F-radiolabeled silicon fluoride acceptor moiety and a gallium chelator complex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET MRI Imaging
Description: rhPSMA-7.3 (18F) PET MRI imaging will be conducted once at baseline and a second time within one year of the initial scan.
Study: NCT05441917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sanae method with LED
Description: Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and phototherapy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sanae method with Radiofrecuency
Description: Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and radiofrequency.
Study: NCT04886453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced general anesthesia without morphine
Description: Balanced general anesthesia without morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard general anesthesia balanced with morphine
Description: Standard general anesthesia balanced with morphine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data collection
Description: Data collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: Data collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of pain
Description: visual analog scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of pain
Description: visual analog scale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recovery quality score
Description: QoR15 questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recovery quality score
Description: QoR15 questionnaire
Study: NCT05805098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Starting on day 1, venetoclax will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2 and 400 mg on day 3. The patient then continues to take the 400mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: On day 1, homoharringtonine 1 mg/m2 IV will be given, and will continue for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: On day 1, cytarabine 100 mg/m2 IV will be given, and will continue for 5 days.
Study: NCT04742647

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double cerclage
Description: Two cervical cerlages will be placed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single cerclage
Description: One cerclage will be placed
Study: NCT05493085

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: Ultrasound-guided quadratus lumborum block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural injection
Description: Single Caudal epidural injection
Study: NCT04727086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.3656
Description: BP1.3656 will be administered in tablet form once daily at a dose of 30 µg/day for the first 4 days of the intervention phase, followed by a dose increase to 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once daily in tablet form.
Study: NCT04778774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: Two different nerve block types, Adductor canal block group and Femoral nerve block group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: Two different nerve block types, Adductor canal block group and Femoral nerve block group
Study: NCT05419843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT Arm group
Description: Conditioning regimen Stem cell source Only Bone Marrow With a minimal target dose of 4x108 nucleated cells/kg recipient ideal body weight. If the graft is less rich than the minimum target dose, it can be administered at the discretion to the physician.~GVHD Prophylaxis Prevention of EBV reactivation : Rituximab 150mg/m2 IV at Day+5 post HSCT.
Study: NCT05110274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Overnight Metabolic Flexibility
Description: Participants will spend 13 hours (overnight) in a metabolic chamber where they will be fed a single high-fat supper meal. Energy expenditure, respiratory exchange ratio (RER), and 12-h oxidation of CHO, fat, and protein will be calculated and used to determine metabolic flexibility, i.e. change in RER from baseline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clamp Metabolic Flexibility
Description: Metabolic flexibility with be assessed during a 2-step hyperinsulinemic-euglycemic clamp procedure. The clamp will be performed for four hours, two hours at an insulin dose of 10 mU/m\^2/min and two hours at an insulin dose of 80 mU/m\^2/min. Resting metabolic rate will be determined via hood indirect calorimetry at baseline, before insulin onset, and during the final 30 min of each step of the clamp. Metabolic flexibility will be determined by comparing the resting metabolic rate during baseline and during the final 30 min of each step of the clamp.
Study: NCT06503562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: central nervous system focused treatment program
Description: Pain neuroscience education, breathing exercises and relaxation exercises with guided imagery

Intervention type: OTHER
Group type: OTHER
Intervention: Classical Physiotherapy
Description: All participants will receive conventional physiotherapy five days a week for one month. Transcutaneous electrical nerve stimulation, 15 min hotpack will be applied to the neck and back. Afterwards, mobilisations to the cervical and thoracic spine joints and myofascial release to the upper trapezius muscle will be applied. The patient will be given 3X10 neck active range of motion exercises to do at home every day and self stretches to the muscles in the neck region (SCM, upper trapezius, scalene and pectoral) according to the patient's condition. After the first week, strengthening exercises with isometric and resistive isotonic exercises will be given to the neck and upper back muscles gradually increasing. Patients will not be given any medication and will be asked not to use any medication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Physiotherapy
Description: All participants will receive conventional physiotherapy five days a week for one month. Transcutaneous electrical nerve stimulation, 15 min hotpack will be applied to the neck and back. Afterwards, mobilisations to the cervical and thoracic spine joints and myofascial release to the upper trapezius muscle will be applied. The patient will be given 3X10 neck active range of motion exercises to do at home every day and self stretches to the muscles in the neck region (SCM, upper trapezius, scalene and pectoral) according to the patient's condition. After the first week, strengthening exercises with isometric and resistive isotonic exercises will be given to the neck and upper back muscles gradually increasing. Patients will not be given any medication and will be asked not to use any medication.